Related by context. All words. (Click for frequent words.) 67 Hb A1C 67 serum urate 67 HbA 1c 67 lumbar spine BMD 66 serum phosphate 66 #.#/#.# mmHg [001] 66 sUA 65 glycated hemoglobin HbA1c 65 serum triglycerides 65 hemoglobin A1c HbA1c 65 STRIDE PD 65 glycosylated hemoglobin HbA1c 64 serum potassium 64 serum uric acid 64 fasting plasma glucose FPG 64 CDAI score 64 systolic BP 64 serum glucose 64 baseline HbA1c 64 glycosylated hemoglobin 64 urinary calcium excretion 63 nonfasting triglycerides 63 HbA 1c levels 63 apolipoprotein B 63 LVEF 63 severe exacerbations 63 diastolic BP 63 iPTH 63 creatinine ratio 63 BENICAR HCT 62 intima media thickness 62 fasting plasma glucose 62 hip BMD 62 nonfatal MI 62 Ishak fibrosis score 62 hematological parameters 62 elevated ALT 62 nonsignificant 62 AST ALT 62 HBeAg seroconversion 62 moderate renal impairment 62 annualized relapse 62 urinary albumin 62 aspartate aminotransferase AST 62 postintervention 62 serum creatinine levels 62 irbesartan 62 -#.# mg dL [002] 62 binary restenosis 62 mean serum phosphorus 62 liver histology 62 glomerular filtration rate 62 oxycodone CR 62 flow mediated dilation 62 symptomatic VTE 62 fasting insulin 62 MADRS score 62 glycated hemoglobin 62 serum PSA 62 triglyceride concentrations 62 alanine aminotransferase ALT 62 calculated creatinine clearance 62 PCWP 61 CVD mortality 61 atherogenic dyslipidemia 61 serum BDNF 61 albumin excretion rate 61 colorectal adenoma 61 #.#mmHg 61 urinary N telopeptide 61 periprocedural 61 serum calcium levels 61 PSADT 61 HbA1C 61 DAS# scores 61 hemoglobin A1C 61 urinary calcium 61 Psoriasis Area 61 HbA1C levels 61 dapagliflozin plus 61 gadolinium enhancing lesions 61 intact parathyroid hormone 61 Primary endpoints 61 morphometric vertebral fractures 61 Castration Resistant Prostate Cancer 61 Lucentis monotherapy 61 adenoma recurrence 61 glomerular filtration 61 IPSS 60 serum urate levels 60 elevated LDH 60 PANSS Positive 60 homocysteine concentrations 60 definite stent thrombosis 60 serum IGF 60 mL/min/#.# m 2 60 Montgomery Asberg Depression 60 serum leptin 60 #.#mg/dL 60 specific antigen PSA 60 alanine aminotransferase 60 HDRS 60 achieved ACR# 60 leukocyte count 60 Scale EDSS score 60 LDL cholesterol concentrations 60 HER2 expression 60 total cholesterol LDL 60 postoperative mortality 60 Crohn Disease Activity 60 advanced adenoma 60 liver enzymes ALT 60 multivariate adjustment 60 HDL Cholesterol 60 ATACAND 60 CR nPR 60 biochemical relapse 60 serum phosphorous 60 -#.# mg dL [001] 60 retinal thickness 60 natriuresis 60 serum cortisol 60 glycated hemoglobin levels 60 hemoglobin Hb 60 HbA1c levels 60 β blockers 60 thromboembolic 60 serum lipid levels 60 FOLPI 60 tHcy 60 HOMA IR 60 PASI scores 60 atheroma volume 60 nonfatal myocardial infarction 60 plasma homocysteine 60 Secondary efficacy endpoints 60 serum sodium 60 Alzheimer Disease Assessment 60 glycemia 60 hyperphenylalaninemia HPA due 60 tirofiban 60 peak VO2 60 serum vitamin D 60 lactate dehydrogenase LDH 60 pCR 60 8mg/kg 60 noncardiovascular mortality 60 serum testosterone 60 serum phosphorus 60 mammographic density 60 echocardiographic parameters 60 serum homocysteine 60 salivary flow 59 plasma cortisol 59 transaminases 59 -#.# log# 59 aspartate aminotransferase 59 Microalbuminuria 59 serum ALT 59 plasma HCV RNA 59 fasting plasma 59 lispro 59 mineral density 59 serum phosphate levels 59 serum calcium 59 malondialdehyde MDA 59 highest tertile 59 HbA 1C 59 cardiovascular morbidity 59 mg BID dose 59 umol L 59 fasting glucose levels 59 blood Phe levels 59 left ventricular diastolic 59 baseline serum creatinine 59 KIF6 carriers 59 Index CDAI 59 albuminuria 59 symptom exacerbation 59 CLA supplementation 59 glucose insulin 59 lumbar spine bone 59 infarct size 59 SCr 59 nonfasting triglyceride levels 59 insulin detemir 59 paraprotein 59 proteinuria 59 bone marrow reticulin 59 rosuvastatin #mg 59 transaminase levels 59 dizziness nausea diarrhea 59 Secondary endpoints included 59 triacylglycerol concentrations 59 Negative Symptom Scale 59 aminotransferases 59 alanine transaminase ALT 59 albumin excretion 59 paricalcitol 59 prospectively stratified 59 glycosylated hemoglobin levels 59 hematologic toxicity 59 HDL C 59 nondiabetic patients 59 elevated creatinine 59 EDARBI 59 BEXXAR Therapeutic Regimen 59 macrovascular 59 arterial thromboembolic events 59 nonfatal stroke 59 serum estradiol 59 somatostatin analog 59 inducible nitric oxide synthase 59 SGPT 59 β blocker 59 corticosteroid dose 59 lipid peroxidation 59 biochemical recurrence 59 HbA1c 59 hematologic adverse 59 multivariable analysis 59 urinary excretion 59 prednisone prednisolone plus 59 nicardipine 59 hemoglobin concentration 59 pulmonary capillary wedge 59 ACR# ACR# 58 CI -#.# 58 serum clusterin levels 58 macroalbuminuria 58 EDSS score 58 lipoprotein Lp 58 ACR# responses 58 clinicopathological features 58 ADCS ADL 58 fasting triglycerides 58 severe renal impairment 58 urine albumin 58 thyroid stimulating hormone 58 HAM D# scores 58 advanced adenomas 58 FDA defined valvulopathy 58 plasma leptin 58 4mg/kg 58 Prehypertension 58 Albuminuria 58 fosamprenavir 58 unfractionated heparin UFH 58 Levels Linked 58 pulmonary exacerbations 58 Erythropoietic therapies may 58 -#.# mmHg 58 eplerenone 58 nephrotoxicity 58 sodium nitroprusside 58 APTIVUS r 58 CNS systemic embolism 58 OGTT 58 DAS# remission 58 Myelosuppression 58 hemoglobin concentrations 58 rCBF 58 #mg/day [002] 58 strontium ranelate 58 polyp recurrence 58 Subgroup analyzes 58 Proteinuria 58 hematologic parameters 58 sUA levels 58 Polyp Prevention Trial 58 LDL Cholesterol 58 ADAS Cog 58 PSA nadir 58 QTcF 58 ULORIC 58 ACR# response 58 CsA 58 NSTE ACS 58 antioxidant supplementation 58 carotid artery intima media 58 tolvaptan 58 mg TID 58 microvessel density 58 EtOH 58 univariate analysis 58 platelet reactivity 58 diameter stenosis 58 HER2 overexpression 58 Cmax 58 serum parathyroid hormone 58 undetectable HBV DNA 58 urinary oxalate 58 thyrotropin 58 urinary cortisol 58 carotid IMT 58 Platelet counts 58 Main Outcome Measure 58 CNS LS 58 QTc intervals 58 cis retinoic acid 58 benazepril 58 CK # plasma 58 antibody titer 58 dose dependently 58 #mmHg [001] 58 triacylglycerol 58 platelet aggregation 58 tipranavir r 58 fructosamine 58 baseline serum bilirubin 57 systemic corticosteroid 57 Kaplan Meier estimates 57 mmHg p = 57 mmHg diastolic 57 mL/min/#.# m2 57 mEq L 57 QTc interval 57 avosentan 57 μmol L 57 #.#mmol L [001] 57 bezafibrate 57 hsCRP 57 natriuretic peptides 57 eGFR 57 HGPIN 57 rimonabant #mg 57 Expanded Disability Status 57 NPH insulin 57 LEXIVA r 57 -#.# ± [002] 57 cardiovascular calcification 57 apo B 57 urinary albumin excretion 57 serum CRP 57 receiving golimumab 57 coronary stenosis 57 serotonin synthesis 57 flutamide 57 ADCS CGIC 57 ANCOVA 57 fasting blood glucose 57 symptomatic intracranial hemorrhage 57 serum folate concentrations 57 relapsed MM 57 complete cytogenetic response 57 periprocedural MI 57 creatinine clearance CrCl 57 estimated glomerular filtration 57 NMIBC 57 MMSE score 57 abnormal p# biomarker 57 ARB telmisartan 57 μg L 57 hsCRP levels 57 placebo fluoxetine 57 hepatic glucose production 57 elevated serum creatinine 57 Renal Insufficiency 57 Score DAS# 57 statistically significant p = 57 perioperative mortality 57 histologically confirmed 57 creatinine clearance 57 lipid lowering agents 57 D dimer 57 thyroglobulin 57 Non inferiority 57 TEAEs 57 sodium excretion 57 TIMP 1 57 ng dL 57 p = #.# [003] 57 protein excretion 57 serum lipids 57 Secondary endpoints 57 aminotransferase levels 57 plasma homocysteine levels 57 multivariable adjusted 57 ejection fractions 57 aminotransferase 57 linaclotide treated 57 serum creatinine 57 extrapyramidal symptoms 57 serologically active patients 57 BYSTOLIC 57 ACTEMRA TM 57 Cardiorespiratory fitness 57 Hyperlipidemia 57 blood Phe 57 ST Segment Elevation 57 confidence intervals CIs 57 hormone receptor negative 57 Mortality Risk 57 secondary efficacy endpoint 57 Ejection Fraction 57 SGOT 57 carotid intima media 57 desvenlafaxine succinate 57 azilsartan medoxomil 57 urate levels 57 plasma folate 57 mmol l 57 plasma lipids 57 magnesium intake 57 tHcy concentrations 57 myocardial infarction stroke 57 BENICAR 57 SSRI SNRI 57 salmeterol fluticasone propionate 57 plasma triglycerides 57 â ‰ ¥ 57 % Confidence Interval 57 steroid dexamethasone 57 univariate 57 hepatic enzymes 57 fraction LVEF 57 TURBT 57 TLUS 57 carotid plaque 57 serum selenium 57 serum aminotransferase levels 57 Rating Scale MADRS 57 tertiles 57 baseline FEV 57 mean ± SEM 57 ACE Inhibitor 57 cerebral perfusion 57 QTc 57 Bone Mineral Density 57 troponin T 56 serum triglyceride 56 SUVmax 56 baseline A1C 56 lanthanum carbonate 56 CK MB 56 triglyceride concentration 56 metformin sulfonylurea 56 left ventricular systolic 56 recurrent venous thromboembolism 56 CrCl 56 Hypotension 56 perioperative complications 56 GnRH agonist 56 candesartan 56 ischemia driven 56 hyperhomocysteinemia 56 REYATAZ r arm 56 #mg BID [003] 56 R# #mg BID 56 microalbuminuria 56 mmol L 56 metabolite concentrations 56 Brief Psychiatric 56 plus methotrexate 56 hemoglobin A1c levels 56 CHD mortality 56 liver transaminases 56 Pharmacokinetic parameters 56 Folfox 56 plasma pharmacokinetics 56 A1c levels 56 cytoreductive nephrectomy 56 abdominal adiposity 56 ALT elevations 56 HMG CoA reductase inhibitors 56 Tiotropium 56 urothelial 56 selenium supplementation 56 serum uric acid sUA 56 carotid stenosis 56 Lp PLA 2 56 ARCALYST ® 56 Negative Syndrome 56 hepatic function 56 achieved statistical significance 56 platelet inhibition 56 atorvastatin #mg 56 postoperative AF 56 GnRH agonists 56 mineral density BMD 56 lymphocytosis 56 radical nephrectomy 56 nonvertebral fractures 56 mRNA expression 56 lymphocyte counts 56 serum concentrations 56 fibrinolysis 56 serum bilirubin 56 Viral load 56 angiotensin converting enzyme ACE 56 p = .# [002] 56 HDL triglycerides 56 6MWD 56 thickness CIMT 56 thromboembolic events 56 angiotensin converting enzyme 56 BPH Symptom Score 56 IFN beta 56 IIIa inhibitor 56 pyrexia mucositis sepsis febrile 56 plasma glucose 56 mg BID 56 postoperative morbidity 56 mcg mL 56 elevated LDL cholesterol 56 TP# mutations 56 mcg QD 56 androgen suppression 56 Main Outcome Measures 56 CDAI 56 serum ferritin 56 serum PTH 56 clinically meaningful improvement 56 antihypertensive medications 56 afterload 56 mTSS 56 simvastatin #mg 56 IBDQ 56 OADs 56 transaminase elevations 56 Cholinesterase Inhibitors 56 Cystatin C 56 apnea hypopnea index 56 Androgen 56 C telopeptide 56 angiotensin converting enzyme inhibitors 56 mol L 56 statin monotherapy 56 HBV DNA 56 apnea hypopnea 56 F2 isoprostanes 56 Hemoglobin A1c 56 specific alkaline phosphatase 56 discontinuations due 56 ALT AST 56 Severity Index PASI 56 oral antidiabetic medication 56 PUFA intake 56 moderate hepatic impairment 56 beta blocker therapy 56 NIHSS score 56 cardiovascular mortality 56 mcg BID 56 hemoglobin A1c 56 Ramipril 56 IFN α 56 Depressive Symptoms 56 laboratory abnormalities 56 certolizumab 56 serum HBV DNA 56 ABCB1 56 neutrophil counts 56 triglycerides TG 56 daunorubicin 56 LEXIVA 56 gastric pH 56 transferrin saturation 56 macrophage infiltration 56 WOMAC scores 56 Hb A1c 56 ACE inhibitor ramipril 56 hemodilution 56 Endothelial Function 56 C Reactive Protein 56 sweat chloride 56 mmHg 56 airway responsiveness 56 lowest tertile 56 Montgomery Åsberg Depression 56 atherogenic lipids 56 #.#g/day 56 leukocyte counts 56 KOMBIGLYZE XR 56 coronary revascularization 56 HBV DNA levels 56 splenectomized patients 56 thromboembolism 56 quetiapine XR 56 serum lipid 56 vWF 56 Serum creatinine 56 Kaplan Meier analysis 56 timepoints 56 DOXIL 56 CSBMs 56 LV dysfunction 56 statistical significance p 56 Cardiopulmonary bypass 56 plasma selenium 56 postprandial glucose PPG 56 nmol l 56 infliximab monotherapy 56 Univariate analysis 56 mean baseline HbA1c 56 rheumatoid factor 56 multivariate Cox 56 ANOVA 56 YMRS 56 Recurrent Stroke 55 cinacalcet 55 creatinine levels 55 x ULN 55 trough FEV1 55 fatal myocardial infarction 55 mucosal healing 55 tertile 55 apo B apo AI 55 Capacity FVC 55 atypical ductal hyperplasia 55 soluble CD# ligand 55 Ranolazine 55 aspirin clopidogrel 55 virologic response 55 contrast induced nephropathy 55 inflammatory biomarkers 55 lignan intake 55 severe periodontitis 55 colesevelam HCl 55 Creatinine 55 Abdominal Fat 55 vaginal progesterone gel 55 visceral adiposity 55 LV ejection fraction 55 vitamin K1 55 dose clopidogrel 55 lymphocyte count 55 candesartan cilexetil 55 coadministration 55 cystatin C 55 See CLINICAL PHARMACOLOGY 55 P = .# 55 abciximab 55 Exacerbations 55 nonfasting 55 diastolic blood pressures 55 triiodothyronine 55 estramustine 55 NHANES III 55 primary hypercholesterolemia 55 Relapsing Remitting Multiple Sclerosis 55 femoral neck BMD 55 mesalamine granules 55 endometrial thickness 55 Events MACE 55 Prostate specific antigen 55 elevated homocysteine 55 neoadjuvant therapy 55 Secondary endpoints include 55 patients undergoing CABG 55 hippocampal volume 55 NYHA functional class 55 recurrent glioblastoma multiforme 55 log# copies mL 55 HSCT 55 NLX P# 55 immunoreactivity 55 serum cholesterol 55 dyslipidaemia 55 conjugated equine estrogen 55 elevated transaminases 55 preintervention 55 central corneal thickness 55 total cholesterol triglycerides 55 serum HCV RNA 55 GSTM1 55 REYATAZ ritonavir 55 mIU L 55 IOP lowering 55 Natalizumab 55 anginal pain 55 Subgroup analysis 55 multivariate analyzes 55 Cytogenetic 55 hypercalciuria 55 MDRD 55 PREZISTA r arm 55 T2 lesion volume 55 fasting serum 55 Pain Intensity 55 clinico pathological 55 mg/m2 dose 55 EDSS scores 55 Decitabine 55 phytoestrogen intake 55 serum prostate 55 dose Iluvien 55 bioavailable testosterone 55 DLTs 55 antigen PSA levels 55 c reactive protein 55 detrusor overactivity 55 placebo dexamethasone 55 isolated systolic hypertension 55 hydroxymethyl coenzyme 55 8 OHdG 55 nonsignificant difference 55 bronchial reactivity 55 NIHSS 55 colon rectal 55 autoantibody levels 55 risedronate Actonel 55 FOLFOX4 55 intestinal permeability 55 Oxidized LDL 55 serum testosterone levels 55 recurrent VTE 55 postdose 55 adiponectin concentrations 55 serum triglyceride levels 55 serum folate 55 ALND 55 Scale EDSS 55 Histologic 55 Hemolysis 55 R0 resection 55 kaempferol 55 -#.# log# copies mL 55 EBMT criteria 55 thiazide diuretics 55 SGRQ 55 ruboxistaurin 55 esophageal carcinoma 55 teriflunomide 55 clinically meaningful reductions 55 mm Hg diastolic 55 mU liter 55 MetS 55 UPDRS 55 angiotensin II receptor blockers 55 beta carotene supplementation 55 neutropenia dehydration dyspnea 55 #.#/#.# mm Hg [001] 55 #.#/#.# mm Hg [003] 55 haematologic 55 Homocysteine 55 asymptomatic carotid stenosis 55 PRADAXA #mg 55 HAQ DI 55 familial AF 55 airway hyperresponsiveness 55 SHBG levels 55 lipid lowering therapy 55 NIH CPSI 55 RAS blockers 55 prospectively defined 55 dose statin therapy 55 budesonide pMDI 55 UPDRS scores 55 alanine transaminase 55 oxycodone IR 55 plasma renin activity 55 hypogonadal 55 mesangial 55 ACEI 55 CIMZIA TM 55 A1C levels 55 neoadjuvant chemotherapy 55 g dl 55 Index CDAI score 55 mmol 55 intensive statin therapy 55 HIV HCV coinfected 55 eicosapentaenoic acid 55 normal ULN 55 composite endpoint 55 BPS IC 55 LDL triglycerides 55 Kidney Disease Outcomes 55 ACR Pedi 55 fasting glucose 55 myocardial uptake 55 NATRECOR R 55 hypopneas 55 mild renal insufficiency 55 pT2 55 Postoperative 55 serum markers 55 μg kg 55 treatment emergent adverse 55 statistically significant p 55 abacavir lamivudine 55 ARIXTRA 55 preoperative PSA 55 Fasting blood glucose 55 lipid parameters 55 distensibility 55 -#.# mm Hg 55 solifenacin 55 serum bicarbonate 55 pg mL 55 vitro cytotoxicity 55 locoregional recurrence 55 FOLFIRI 55 Postoperative complications 55 systemic embolism 55 cholesterol LDL C 55 nonaspirin 55 mg simvastatin 55 LPS induced 55 dietary calcium intake 55 imipenem 55 hydroxyvitamin D levels 55 impaired endothelial 55 posaconazole 55 bypass graft CABG surgery 55 prolactin levels 55 febuxostat 54 lopinavir r arm 54 N telopeptide 54 ug kg 54 Score IPSS 54 alkaline phosphatase ALP 54 TNFalpha 54 plasma urate 54 serum LDL cholesterol 54 Acetate Rectal Suppositories 54 sustained virological response 54 Triglyceride 54 #Gy 54 Skin sterol 54 Calcium intake 54 metabolic parameters 54 acromegalic patients 54 posttreatment 54 thrombotic events 54 virologic failure 54 timepoint 54 exhaled NO 54 upper gastrointestinal bleeding 54 pharmacodynamic PD 54 CD4 + cell 54 mmHg systolic 54 dose proportionality 54 serum albumin 54 CIN3 54 aPTT 54 pT3 54 ibandronate 54 plasma fibrinogen 54 ß carotene 54 endometrial hyperplasia 54 loop diuretics 54 Thrombolysis 54 Comorbidities 54 CP CPPS 54 ertapenem 54 HMG CoA reductase inhibitor 54 thyrotropin levels 54 fasting plasma insulin 54 lymphadenectomy 54 risk reducing salpingo 54 titrated glipizide 54 salivary cortisol 54 LDL particle 54 Non Responders 54 Abciximab 54 venous thromboembolic events 54 renal cell carcinomas 54 pyridostigmine 54 PANSS scores 54 neutropaenia 54 placebo p 54 arterial thromboembolism 54 IFN alfa 54 malondialdehyde 54 isoprostane 54 CRESTOR #mg 54 SIMPADICO 54 unstable angina pectoris 54 COZAAR 54 demonstrated clinically meaningful 54 Ischemic 54 vasodilatation 54 cerebral oxygen saturation 54 logistic regression model 54 IL 1ß 54 activated partial thromboplastin 54 elevated uric acid 54 methotrexate monotherapy 54 B vitamin supplementation 54 MACCE 54 erythrocyte sedimentation rate 54 myocardial viability 54 XIENCE V demonstrated 54 Doxil ® 54 Celecoxib 54 PANSS 54 Endothelial dysfunction 54 tamsulosin 54 myeloperoxidase 54 atherothrombotic disease 54 pharmacodynamic parameters 54 idraparinux 54 cerebrovascular events 54 Antitumor 54 dose cytarabine 54 VcMP 54 ximelagatran 54 cranial irradiation 54 #mg/day [001] 54 WOMAC pain 54 ocular adverse 54 Hemodialysis Patients 54 Fibrates 54 plasma glucose levels 54 FOSRENOL ® 54 covariate 54 recurrent ischemic 54 Tumor shrinkage 54 nmol L 54 pressor response 54 DAS# [002] 54 #/#mmHg 54 foveal thickness 54 dosing cohort 54 Localized Prostate Cancer 54 UPDRS motor 54 cells uL 54 del 5q MDS 54 chemoradiotherapy 54 GFT# 54 nonobstructive CAD 54 endoscopic remission 54 Pioglitazone 54 Key secondary endpoints 54 angiotensin converting enzyme inhibitor 54 euthyroid 54 adjuvant radiotherapy 54 T2DM 54 placebo p = 54 fractional shortening 54 Systolic Blood Pressure 54 ALT normalization 54 #ng/ml 54 nonresponders 54 creatinine 54 ziprasidone 54 overt nephropathy 54 calcium excretion 54 5-FU/LV 54 adrenal function 54 Vertebral Fractures 54 arterial oxygen saturation 54 statistically nonsignificant 54 subscale scores 54 inflammatory lesions 54 nmol liter 54 SHBG 54 myocardial perfusion 54 lifetime abstainers 54 serum GGT 54 #OHD levels 54 undetectable viral 54 PRADAXA 54 concomitant medications 54 systolic dysfunction 54 evaluable subjects 54 Multiple Ascending Dose 54 adjunctive placebo 54 fluvastatin 54 subtrochanteric 54 bone resorption 54 IRLS score 54 preoperative chemotherapy 54 #.#mmol L [002] 54 olmesartan 54 p# activation 54 serum insulin 54 coronary calcification 54 CR CRu 54 Hazard Ratio 54 confidence interval #.#-#.# 54 gallstone disease 54 spontaneous preterm delivery 54 FEV1 54 microvascular complications 54 hypertensives 54 ALT elevation 54 PEDF 54 reinfarction 54 Invasive Breast Cancer 54 endogenous EPO 54 hydroxyvitamin D 54 Primary Endpoint 54 NATRECOR ® 54 artery stenosis 54 lactate dehydrogenase 54 Randomized Evaluation 54 H. pylori eradication 54 metabolic acidosis 54 HDL cholesterol concentrations 54 dehydroepiandrosterone sulfate 54 ALT flares 54 leucopenia 54 LDL HDL 54 selenium intake 54 vascular reactivity 54 cardiovascular hospitalization 54 adefovir treated